vorinostat has been researched along with Nasopharyngeal Neoplasms in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A novel drug combination of a proteasome inhibitor, bortezomib, and a histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), was tested in nasopharyngeal carcinoma (NPC), both in vitro and in vivo." | 7.79 | Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. ( Chiang, AK; Ho, DN; Hui, KF; Lam, BH; Tsao, SW, 2013) |
| "A novel drug combination of a proteasome inhibitor, bortezomib, and a histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), was tested in nasopharyngeal carcinoma (NPC), both in vitro and in vivo." | 3.79 | Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. ( Chiang, AK; Ho, DN; Hui, KF; Lam, BH; Tsao, SW, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hui, KF | 2 |
| Lam, BH | 1 |
| Ho, DN | 2 |
| Tsao, SW | 1 |
| Chiang, AK | 2 |
| Lan, MY | 1 |
| Yang, WL | 1 |
| Lin, KT | 1 |
| Lin, JC | 1 |
| Shann, YJ | 1 |
| Ho, CY | 1 |
| Huang, CY | 1 |
| Schwartz, BE | 1 |
| Hofer, MD | 1 |
| Lemieux, ME | 1 |
| Bauer, DE | 1 |
| Cameron, MJ | 1 |
| West, NH | 1 |
| Agoston, ES | 1 |
| Reynoird, N | 1 |
| Khochbin, S | 1 |
| Ince, TA | 1 |
| Christie, A | 1 |
| Janeway, KA | 1 |
| Vargas, SO | 1 |
| Perez-Atayde, AR | 1 |
| Aster, JC | 1 |
| Sallan, SE | 1 |
| Kung, AL | 1 |
| Bradner, JE | 1 |
| French, CA | 1 |
| Tsang, CM | 1 |
| Middeldorp, JM | 1 |
| Tsao, GS | 1 |
| Gray, SG | 1 |
| Qian, CN | 1 |
| Furge, K | 1 |
| Guo, X | 1 |
| Teh, BT | 1 |
5 other studies available for vorinostat and Nasopharyngeal Neoplasms
| Article | Year |
|---|---|
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Line | 2013 |
Using computational strategies to predict potential drugs for nasopharyngeal carcinoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Gene Expression Regulatio | 2014 |
Differentiation of NUT midline carcinoma by epigenomic reprogramming.
Topics: Acetylation; Animals; Carcinoma, Squamous Cell; Cell Differentiation; Child; Female; Gene Knockdown | 2011 |
Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Cell Proliferation; Epstein | 2012 |
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines.
Topics: Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Enzyme Inhibitors; Gene Expression Profiling; Gene | 2004 |